GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Biotechnology Corp (ROCO:3176) » Definitions » Issuance of Debt

Medigen Biotechnology (ROCO:3176) Issuance of Debt : NT$306 Mil (TTM As of Sep. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Medigen Biotechnology Issuance of Debt?

Medigen Biotechnology's Issuance of Debt for the three months ended in Sep. 2024 was NT$88 Mil.

Medigen Biotechnology's Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2024 was NT$306 Mil.

Medigen Biotechnology Issuance of Debt Historical Data

The historical data trend for Medigen Biotechnology's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Biotechnology Issuance of Debt Chart

Medigen Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 315.00 422.00 370.00 2,063.25 239.70

Medigen Biotechnology Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -60.00 159.70 49.00 10.00 87.50

Medigen Biotechnology Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$306 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigen Biotechnology Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Medigen Biotechnology's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Medigen Biotechnology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Biotechnology Corp (ROCO:3176) » Definitions » Issuance of Debt
Comparable Companies
ROCO:6838 ROCO:06891 ROCO:4726 ROCO:4167 ROCO:6676 TPE:1734 TPE:6657 ROCO:6885 ROCO:6492 ROCO:6634 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560
Website
https://www.medigen.com.tw
Medigen Biotechnology Corp is a biopharmaceutical company engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The company has four segments: Nucleic acid department: segment, which derives maximum revenue, is responsible for services of testing reagents, instruments and inspection on behalf of others; New drug and vaccine research and development segment: responsible for the development and relevant services of new drugs and vaccine; Cytotherapy department: responsible for research and development and relevant services of cytotherapy; and Generic drug, aesthetic medicine product and dietary supplement segment is responsible for production and sales and relevant services of western medicine, aesthetic medicine product and dietary supplement.

Medigen Biotechnology Headlines

No Headlines